Relay Therapeutics Inc (RLAY) concluded trading on Thursday at a closing price of $3.41, with 4.18 million shares of worth about $14.25 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -62.11% during that period and on March 13, 2025 the price saw a loss of about -6.83%. Currently the company’s common shares owned by public are about 167.76M shares, out of which, 127.17M shares are available for trading.
Stock saw a price change of -2.01% in past 5 days and over the past one month there was a price change of -8.82%. Year-to-date (YTD), RLAY shares are showing a performance of -17.23% which decreased to -64.11% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.02 but also hit the highest price of $10.72 during that period. The average intraday trading volume for Relay Therapeutics Inc shares is 2.21 million. The stock is currently trading -6.00% below its 20-day simple moving average (SMA20), while that difference is down -17.25% for SMA50 and it goes to -42.75% lower than SMA200.
Relay Therapeutics Inc (NASDAQ: RLAY) currently have 167.76M outstanding shares and institutions hold larger chunk of about 75.24% of that.
The stock has a current market capitalization of $578.07M and its 3Y-monthly beta is at 1.53. It has posted earnings per share of -$2.40 in the same period. It has Quick Ratio of 15.95 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RLAY, volatility over the week remained 11.19% while standing at 9.31% over the month.
Stock’s fiscal year EPS is expected to rise by 2.79% while it is estimated to decrease by -3.58% in next year. EPS is likely to grow at an annualized rate of 0.41% for next 5-years, compared to annual growth of -23.05% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on September 10, 2024 offering a Buy rating for the stock and assigned a target price range of between $10.60 and $16 to it. Coverage by Goldman stated Relay Therapeutics Inc (RLAY) stock as a Buy in their note to investors on September 10, 2024, suggesting a price target of $20 for the stock. On September 10, 2024, Oppenheimer Downgrade their recommendations, while on May 10, 2024, Barclays Upgrade their ratings for the stock with a price target of $15. Stock get a Hold rating from Jefferies on April 20, 2023.
